Piper Jaffray analyst Matt O'Brien raised his price target on Boston Scientific to $38 after its better than expected Q2 results. The analyst notes that the quarter was "balanced across business segments and geographies with Rhythm Management", adding that the management also narrowed higher its FY18 organic growth rate targets. O'Brien also cites another quarter of strength in the emerging markets, keeping his Overweight rating on expectations of "expanded product indications, clinical data in Q3, and the successful integration of several new acquisitions".